Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations

Phase 2 Completed 63 enrolled Kura Oncology, Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Phase II study to investigate the antitumor activity in terms of objective response rate (ORR) of tipifarnib in subjects with advanced tumors that carry HRAS mutations and for whom there is no standard curative therapy available.

Timeline

Start: 2015-05-13
Primary completion: 2020-12-14
Completion: 2020-12-14

Publications

Ho AL, Brana I, Haddad R, Bauman J, Bible K, Oosting S, Wong DJ, Ahn MJ, Boni V, Even C, Fayette J, Flor MJ, Harrington K, Kim SB, Licitra L, Nixon I, Saba NF, Hackenberg S, Specenier P, Worden F, Balsara B, Leoni M, Martell B, Scholz C, Gualberto A. Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations. J Clin Oncol. 2021 Jun 10;39(17):1856-1864. doi: 10.1200/JCO.20.02903. Epub 2021 Mar 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	tipifarnib	Small molecule	600 mg	Oral
Subject	tipifarnib	Small molecule	900 mg	Oral

Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations

Summary

Timeline

Publications

Drugs

Indications